BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, June 19, 2026
Home » Authors » Cormac Sheridan

Articles by Cormac Sheridan

Genmab Shares Rise on Ofatumumab CLL Data

Dec. 10, 2008
By Cormac Sheridan
Shares in Genmab A/S gained as much as 13 percent during trading Tuesday following the release of additional clinical data on Arzerra (ofatumumab), an anti-CD20 monoclonal antibody undergoing a Phase III trial in patients with refractory chronic lymphocytic leukemia (CLL). (BioWorld International)
Read More

Newron Puts $24.8M Safety Net in Place for Partner Discussions

Dec. 10, 2008
By Cormac Sheridan

Basilea Falls as FDA Delays Ceftobiprole Decision Again

Dec. 3, 2008
By Catherine Hollingsworth and Cormac Sheridan

Basilea Falls as FDA Delays Ceftobiprole Decision Again

Dec. 1, 2008
By Catherine Hollingsworth and Cormac Sheridan
The FDA again delayed its review of cephalosporin antibiotic ceftobiprole due to unresolved "data integrity issues," an unexpected setback for Swiss biotech Basilea Pharmaceutica Ltd. and co-development partner Johnson & Johnson Pharmaceutical Research & Development LLC. (BioWorld Today)
Read More

Merrion Stock Surges on $58M Novo Nordisk Deal

Nov. 26, 2008
By Cormac Sheridan
DUBLIN, Ireland – Shares in Merrion Pharmaceuticals plc (DUBLIN:MERR) surged 42 percent Monday on news that the company had secured a licensing deal with Novo Nordisk for the oral delivery of the latter company's proprietary insulin analogues. (BioWorld International)
Read More

CHMP Votes Unanimously in Favor of Ceftobiprole

Nov. 26, 2008
By Cormac Sheridan

Curalogic Management Wants to Call it a Day

Nov. 26, 2008
By Cormac Sheridan

Ganymed Gets €65M for Cancer-Specific Antibodies

Nov. 19, 2008
By Cormac Sheridan
No Abstract BioWorld Today CorrespondentGanymed Pharmaceuticals AG landed one of Europe's landmark private equity deals of 2008, a €65 million (US$82.2 million) fourth financing round that will fund preclinical and early clinical development of a broad pipeline of its cancer-specific antibody therapies in multiple oncology indications.
Read More

Recipharm Takes Control over AstraZeneca Biologics Facility

Nov. 19, 2008
By Cormac Sheridan

Ganymed Gets €65M for Cancer-Specific Antibodies

Nov. 19, 2008
By Cormac Sheridan
No Abstract BioWorld International CorrespondentGanymed Pharmaceuticals AG landed one of Europe's landmark private equity deals of 2008, a €65 million (US$82.2 million) fourth financing round that will fund preclinical and early clinical development of a broad pipeline of its cancer-specific antibody therapies in multiple oncology indications.
Read More
Previous 1 2 … 202 203 204 205 206 207 208 209 210 … 335 336 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing